学科与关键词
关键词
PolyphenylalanineEGFR-TKI resistanceNon-small cell lung cancer
- Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancersCaolin, Wang; Shan, Xu; Liang, Peng; Bingliang, Zhang; Hong, Zhang; Yingying, Hu; Pengwu, Zheng; Wufu, ZhuJournal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34(1): 203-217.被引 3
- Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung AdenocarcinomaGuan, X. -H.; Weng, C. -D.; Chen, H. -J.; Zhou, Q.; Zhang, X. -C.; Wu, Y. -L.; Yang, J. -J.
- A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)Zhang, L.; Fang, W.; Yu, Q.; Zhang, H.; Wu, G.; Wu, D.; Lin, Y.; Zhu, J.; Chen, J.; Hu, X.; Lan, B.; Zhou, Z.; Lin, H.; Wang, Z.; Lei, X.; Pan, S.; Chen, L.; Zhang, J.; Kong, T.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
